Seventy-five women undergoing elective day case gynaecological surgery were randomised into one of three groups to receive an oral formulation of midazolam IV solution 10 mg, temazepam 20 mg or placebo for premedication. The two treatment groups showed a significant reduction in anxiety score compared with placebo (P< 0.002 and P< 0.04 for placebo compared with temazepam and midazolam respectively). Similarly the treatment groups showed a significantly greater sedation score compared with placebo. Recovery as assessed by letter deletion and memory tests was no worse for the treatment groups than for placebo. Patient acceptance of the two treatment groups was significantly greater than that of placebo. There was no significant difference between treatment groups with respect to anxiolysis, sedation or recovery. As a day case premedicant, midazolam IV solution 10 mg orally was found to be as effective as temazepam 20 mg and superior to placebo, in terms of anxiolysis and sedation, but did not offer any clinical advantage over temazepam in this setting.
A principal aim of premedication in modern anaesthesia is to relieve preoperative fear and anxiety, the reported incidence of which varies from 11 % to 80%.1 Oral premedication with benzodiazepines has been increasing in popularity and temazepam is now commonly used. 2 -4 More recently an oral form of midazolam has been evaluated as a premedicant. 5 . 8 Midazolam is rapidly absorbed and cleared after oral administration. These pharmacokinetic properties of midazolam suggest that it may be a very suitable drug for day case premedication, where the need for preoperative anxiolysis is coupled with a requirement for rapid postoperative recovery.
Previous controlled clinical trials of midazolam as a premedicant have used a commercial 7.5 mg tablet presentation which is not available in Australia. However, the injectable intravenous (IV) solution is well absorbed orally with identical bioavailability (35%) to the tablet formulation. 9 This trial was conducted to establish the suitability of using the intravenous solution of midazolam in a 10 mg dose, as an oral premedicant prior to day case gynaecological surgery and to compare this solution with temazepam 20 mg orally and placebo.
METHODS
Seventy-five women admitted as day case patients for dilatation and curettage were entered into the study. Informed consent and institutional approval were obtained. Age and weight were noted and baseline pulse and blood pressures recorded. The patient was asked to indicate her level of anxiety on a 10 cm linear analogue scale (LAS), marked 'completely relaxed and at ease' at one end and 'extremely anxious and nervous' at the other. A baseline letter deletion test and a memory recall test were performed. The latter consisted of free recalling pictures of eight everyday objects from a picture card five minutes after studying it for thirty seconds.
Patients were randomly assigned to one of three groups (of 25 each). Group 1 received a placebo premedicant; Group 2 temazepam 20 mg and Group 3 midazolam 10 mg. The premedication drug was presented in 4 ml of flavoured syrup, prepared by the hospital pharmacy into numbered bottles, and was taken with 20 ml of water one hour before the scheduled start of surgery. A midazolam sample was assayed at the end of the trial period and was found to have retained 96.6% of its original midazolam content.
Prior to entering theatre the patients' level of sedation was assessed by one of the authors using a 10 cm LAS marked 'fully awake and alert' at one end and 'failure to rouse on being addressed' at the Anaesthesia was induced by slow injection of propofol and maintained with nitrous oxide and isoflurane in oxygen supplemented by fentanyl 1.0 microgram per kilogram.
Three hours postoperatively, recovery was assessed by the performance of a second letter deletion and memory tests. Patients were questioned as to the presence of any side-effects and their opinion of their premedication.
Descriptive statistics (mean, SD) were used to describe patient demographic data. Groups were compared using the Wilcoxon rank sum and Fisher's exact test as appropriate. All tests were performed to a significance level of 5% (P < 0.05).
RESULTS
Seventy-five women were enrolled in this study. (9) 43 (15) 65 (12) Data from one case were excluded from analyses due to failure to follow protocol with respect to general anaesthesia, leaving 74 analysed results (n = 25 placebo; n = 25 temazepam; n = 24 midazolam).
Patient characteristics
Demographic data are shown in Table I . There were no significant differences between groups.
Anxio/ysis
The preinduction anxiety score 38 (28) placebo; 20 (17) temazepam; 22 (25) midazolam was significantly different to the premedication score for both treatment groups compared to placebo (P < 0.002 and P < 0.04 for placebo compared to temazepam and midazolam respectively). The anxiolytic effect of premedication, as assessed by change in anxiety score and in systolic blood pressure, is shown in Figure I .
There was no significant difference between the temazepam and midazolam groups for any assessment.
Sedation
Sedation scores are detailed in Figure 2 . There was a significantly higher score in the treatment groups compared with placebo but no difference between temazepam and midazolam.
Postoperative recovery
Details of performance of memory and letterdeletion tests are shown in Tables 2 and 3 . Patients in all groups performed less well in psychomotor tests postoperatively. There was a significantly higher letter-deletion score and smaller reduction in score in group 2 (temazepam) compared with groups I and 3 (P < 0.03 and < 0.05 respectively).
Satisfaction with premedication
No patient experienced nausea prior to induction. In response to the question 'Did your premedication relieve your anxiety?" 76% of the 
DISCUSSION
Midazolam is an imidazobenzodiazepine that is completely and rapidly absorbed after oral administration, both in the commercially available tablet form and as the IV solution (Roche in-house report, Personal Communication). The bioavailability is 35%. 9 It reaches peak plasma level in 44 minutes and has an elimination half-life of 112 minutes. 9 This is significantly more rapid than for temazepam. 2, 3 This study had a dual purpose; to determine the premedicant efficacy of 10 mg of IV midazolam solution ingested orally and secondly to compare it with an established oral day case premedicant, temazepam 20 mg.
Previous studies of oral midazolam as a day case premedicant have used a commercial tablet formulation in doses of either 7.5 mg or 15 mg. Raybould and Bradshaw 6 compared these two doses and found that 7.5 mg was no more anxiolytic than placebo, while the 15 mg dose was too sedating. Nightingale and Norman 8 compared midazolam in a dose of 15 mg with temazepam 20 mg and found that the higher dose of midazolam, though providing superior anxiolysis, caused excessive sedation and delay in recovery of psychomotor function. In this study a 10 mg dose significantly increased sedation and improved anxiolysis compared to placebo, without resulting in clinically evident prolonged recovery. This is in contrast to the study by Artru et at. in which intramuscular midazolam was found to be no better than placebo as an anxiolytic.1O
Pulse and blood pressure were measured as objective assessments of premedication. 11 There were no differences between the groups with regard to pulse, however there was a non-significant trend to a fall in systolic blood pressure in the two treatment groups compared to the placebo group. This is consistent with studies comparing temazepam and placeb0 2 and temazepam and diazepam, 3 in which the temazepam resulted in a statistically significant fall in pulse and systolic blood pressure compared to the other groups.
The ability to retain new information beyond the duration of immediate short-term memory is a sensitive test of residual anaesthesia-induced impairment. 12 This postoperative memory test in the present study showed no difference between the three groups. However, post operatively the temazepam group showed a letter deletion score significantly greater than not only the midazolam group but also the placebo group. As the group scores were identical initially this was an unexpected finding and may represent a type 1 error. However, in their comparison of midazolam and temazepam Nightingale and Norman 8 also found an improvement in letter deletion test performance following temazepam premedication, while the midazolam group showed a deterioration.
In conclusion, we found 10 mg of midazolam IV solution taken orally for day case premedication to be as effective as 20 mg of temazepam, in terms of sedation, anxiolysis and patient acceptance, and no different to placebo with respect to postoperative recovery. Both of these agents were found to be significantly better than placebo with respect to efficacy and patient acceptability.
